Saltar al contenido
PivotalWire
Lunes 12 oct 2026SEC · NASDAQ biomédico

Portada›Viernes 5 de diciembre de 2025

Biomédicas del NASDAQ ante la SEC, viernes 5 de diciembre de 2025

Los 42 documentos que 33 empresas del sector presentaron ante la SEC ese día, agrupados por tipo y con el enlace al original en EDGAR.

·

El día, bloque a bloque

Va en color lo que cambia el capital o avisa de un riesgo: las emisiones con precio (424B1, 424B2, 424B4 y 424B5), los 8-K con item 1.02, 1.03, 2.04, 3.01, 3.02 y 4.02, y cualquier documento en el que haya aparecido una frase vigilada, que va citada debajo. Lo demás va en tinta normal. Una cita marcada «por primera vez» es una frase que no estaba en el informe previo del mismo tipo de esa empresa. La etiqueta del formulario lleva a su explicación.

Emisiones y dilución

  1. CAPRCAPRICOR THERAPEUTICS, INC.424B5Nueva emisión de acciones con precioEDGAR
  2. ENVBEnveric Biosciences, Inc.S-3/ACapacidad de emisión registrada (enmienda)EDGAR
    En el documentoContrasplit de accionestexto original ▸…any revisions to any of the forward-looking statements contained herein to reflect future events or developments. iv SELECTED FINANCIAL DATA REFLECTING THE REVERSE STOCK SPLIT On October 23, 2025, we effected a 1-for-12 reverse stock split (the “Reverse Stock Split”), which began trading on a split-adjusted basis on October 28, 2025, pursuant to which every 12 shares of our issued and outstanding shares of Common Stock were reclassified…
  3. FLNAFILANA THERAPEUTICS, INC.424B2Nueva emisión de acciones con precioEDGAR
  4. HYPDHYPERION DEFI, INC.S-3/ACapacidad de emisión registrada (enmienda)EDGAR
    En el documentoContrasplit de accionestexto original ▸…notified by Nasdaq that we had regained compliance with the Minimum Bid Price Rule. Nasdaq Listing Rule 5810(c)(3)(A)(iv) states that any listed company that fails to meet the Minimum Bid Price Rule and has effected a reverse stock split over the prior one-year period, or has effected one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one, will not be eligible for an automatic…
  5. IMTXImmatics N.V.424B5Nueva emisión de acciones con precioEDGAR
  6. IMTXImmatics N.V.424B5Nueva emisión de acciones con precioEDGAR
  7. KALAKALA BIO, Inc.424B5Nueva emisión de acciones con precioEDGAR
    En el documentoDuda sustancial sobre la continuidad de la empresatexto original ▸…balance of approximately $21.1 million as of September 30, 2025. Because we do not have sufficient resources to fund our operations for the next twelve months from the date of this filing, management has substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of asset amounts or the classification of liabilities that might be necessary should we be unable…
    En el documentoAviso de incumplimiento de las reglas de cotizacióntexto original ▸…State of Delaware creating the Series AAA Preferred Stock, and (iv) the satisfaction of other customary closing conditions. Nasdaq Market Value of Listed Securities Deficiency On November 10, 2025, we received a deficiency letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market notifying us that the listing of our common stock was not in compliance with Nasdaq Listing Rule 5550…
  8. LYELLyell Immunopharma, Inc.S-3Capacidad de emisión registradaEDGAR
    En el documentoContrasplit de accionestexto original ▸…investors are cautioned not to unduly rely upon these statements. 7 Table of Contents SELECTED FINANCIAL DATA REFLECTING REVERSE STOCK SPLIT Reverse Stock Split At 5:00 p.m. Eastern Time on May 30, 2025, we effected a 1-for-20 reverse stock split of our common stock (the “Reverse Stock Split”). Based on such Reverse Stock Split, the total number of outstanding shares of common stock was adjusted from 296,161,570 shares to approximately 14,808…
  9. MIRAMIRA PHARMACEUTICALS, INC.424B5Nueva emisión de acciones con precioEDGAR
  10. SCLXScilex Holding Co424B3Prospecto suplementario o de reventaEDGAR
    En el documentoContrasplit de accionestexto original ▸…40. Our Public Warrants are listed on the Nasdaq Capital Market under the symbol “SCLXW.” On December 4, 2025, the closing sale price per warrant of our Public Warrants was $0.20. On April 15, 2025, we effected a reverse stock split of our Common Stock at a ratio of 1-for-35 (the “Reverse Stock Split”). Unless otherwise noted, the share and per share information in the Prospectuses and this prospectus supplement reflects the effect…
  11. SCLXScilex Holding Co424B3Prospecto suplementario o de reventaEDGAR
    En el documentoContrasplit de accionestexto original ▸…40. Our Public Warrants are listed on the Nasdaq Capital Market under the symbol “SCLXW.” On December 4, 2025, the closing sale price per warrant of our Public Warrants was $0.20. On April 15, 2025, we effected a reverse stock split of our Common Stock at a ratio of 1-for-35 (the “Reverse Stock Split”). Unless otherwise noted, the share and per share information in the Prospectuses and this prospectus supplement reflects the effect…
  12. SCLXScilex Holding Co424B3Prospecto suplementario o de reventaEDGAR
    En el documentoContrasplit de accionestexto original ▸…40. Our Public Warrants are listed on the Nasdaq Capital Market under the symbol “SCLXW.” On December 4, 2025, the closing sale price per warrant of our Public Warrants was $0.20. On April 15, 2025, we effected a reverse stock split of our Common Stock at a ratio of 1-for-35 (the “Reverse Stock Split”). Unless otherwise noted, the share and per share information in the Prospectuses and this prospectus supplement reflects the effect…
  13. TARAProtara Therapeutics, Inc.424B5Nueva emisión de acciones con precioEDGAR
  14. AKTXAkari Therapeutics Plc424B3Prospecto suplementario o de reventaEDGAR
  15. BFRIBiofrontera Inc.S-1Capacidad de emisión registradaEDGAR
  16. CAPRCAPRICOR THERAPEUTICS, INC.424B3Prospecto suplementario o de reventaEDGAR
  17. GRMLGreenland Mines LtdS-1Capacidad de emisión registradaEDGAR
  18. LEXXLexaria Bioscience Corp.S-1/ACapacidad de emisión registrada (enmienda)EDGAR
  19. MDCXMedicus Pharma Ltd.424B3Prospecto suplementario o de reventaEDGAR
  20. MNOVMEDICINOVA INCS-3Capacidad de emisión registradaEDGAR
  21. QNRXQuoin Pharmaceuticals Ltd.424B3Prospecto suplementario o de reventaEDGAR
  22. RZLTRezolute, Inc.S-3ASRCapacidad de emisión registradaEDGAR

Participaciones y control

  1. TCRTAlaunos Therapeutics, Inc.SC 13D/ACambio en participación significativaEDGAR

Informes y hechos relevantes

  1. ATYRaTYR PHARMA INC8-KAviso de incumplimiento de cotizaciónEDGAR
  2. INTSINTENSITY THERAPEUTICS, INC.8-KAviso de incumplimiento de cotizaciónEDGAR
  3. NTHINEONC TECHNOLOGIES HOLDINGS, INC.8-KVenta de acciones no registrada (colocación privada)EDGAR
  4. PMCBPharmaCyte Biotech, Inc.8-KAviso de incumplimiento de cotizaciónEDGAR
  5. CAPRCAPRICOR THERAPEUTICS, INC.8-KOtros hechos relevantesEDGAR
  6. CELUCelularity Inc8-KOtros hechos relevantesEDGAR
  7. CRVOCervoMed Inc.8-KOtros hechos relevantesEDGAR
  8. HURATuHURA Biosciences, Inc./NV8-KNuevo acuerdo materialEDGAR
  9. IDYAIDEAYA Biosciences, Inc.8-KOtros hechos relevantesEDGAR
  10. INMBInmune Bio, Inc.8-KOtros hechos relevantesEDGAR
  11. KALAKALA BIO, Inc.8-KNuevo acuerdo materialEDGAR
  12. LYELLyell Immunopharma, Inc.8-KCambio de estatutosEDGAR
  13. MIRAMIRA PHARMACEUTICALS, INC.8-KOtros hechos relevantesEDGAR
  14. OCULOCULAR THERAPEUTIX, INC8-KOtros hechos relevantesEDGAR
  15. SCLXScilex Holding Co8-KNuevo acuerdo materialEDGAR
  16. STOKStoke Therapeutics, Inc.8-KOtros hechos relevantesEDGAR
    En el documentoDesignación de terapia innovadora (breakthrough)texto original ▸…improve neurodevelopment, cognition, and behavior. Zorevunersen has demonstrated the potential for disease modification and has been granted orphan drug designation by the FDA and the EMA. The FDA has also granted zorevunersen rare pediatric disease designation and Breakthrough Therapy Designation for the treatment of Dravet syndrome with a confirmed mutation not associated with gain-of-function, in the SCN1A gene. Stoke has a strategic collaboration with Biogen to develop and commercialize zorevunersen…
  17. TRVITrevi Therapeutics, Inc.8-KCambio en el consejo o la direcciónEDGAR
  18. VTRSViatris Inc8-K/ACambio en el consejo o la direcciónEDGAR

Juntas de accionistas

  1. BCABBioAtla, Inc.DEF 14AConvocatoria de junta de accionistasEDGAR
    En el documentoContrasplit de accionestexto original ▸…by other factors which may be unrelated to the number of shares outstanding, including our business and financial performance, general market conditions, and prospects for future success. Once we have effected the Reverse Stock Split, we must ensure that our stock price trades above $1.00 in the long term. Under a Nasdaq rule that was amended in January 2025, if the Company falls out of compliance with the Minimum Bid Price Requirement…

·

Esto mismo, cada mañana y solo de tus empresas. Sigue a las que te interesen y recibe en tu correo lo que presenten ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Esto no son recomendaciones de inversión. Son hechos públicos verificables en su fuente. Lee siempre el documento original antes de decidir nada. Aviso legal.